NovoCure (NVCR) Free Cash Flow Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 6.28% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 9.63% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 22.80% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 29.36% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -27.72% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -0.27% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 77.20% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -20.37% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.32% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | 6.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.47% |
| Dec 31, 2025 | -31.21% |
| Sep 30, 2025 | -3.72% |
| Jun 30, 2025 | -56.62% |
| Mar 31, 2025 | -74.03% |
| Dec 31, 2024 | -359.99% |
| Sep 30, 2024 | -26.30% |
| Jun 30, 2024 | -36.78% |
| Mar 31, 2024 | -72.60% |
| Dec 31, 2023 | -34.77% |
| Sep 30, 2023 | -43.30% |
| Jun 30, 2023 | -72.66% |
| Mar 31, 2023 | -170.32% |
| Dec 31, 2022 | -66.25% |
| Sep 30, 2022 | 11.07% |
| Jun 30, 2022 | 20.37% |
| Mar 31, 2022 | -9.76% |
| Dec 31, 2021 | -79.47% |
| Sep 30, 2021 | 70.14% |
| Jun 30, 2021 | 68.94% |
| Mar 31, 2021 | 40.71% |
| Dec 31, 2020 | 97.81% |
| Sep 30, 2020 | 141.43% |
| Jun 30, 2020 | 51.94% |
| Mar 31, 2020 | 65.42% |
| Dec 31, 2019 | 31.47% |
| Sep 30, 2019 | 32.88% |
| Jun 30, 2019 | 30.26% |
| Mar 31, 2019 | 40.78% |
| Dec 31, 2018 | 36.67% |
| Sep 30, 2018 | 29.74% |
| Jun 30, 2018 | 30.63% |
| Mar 31, 2018 | 15.47% |
| Dec 31, 2017 | 22.73% |